An open-label study of olanzapine in the first episode of schizophrenia in adolescents

被引：0
|
作者：
Dabokowska, M [1 ]
机构：
[1] Med Acad, Dept Psychiat, Bydgoszcz, Poland
来源：
EUROPEAN PSYCHIATRY | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：115S / 115S
页数：1
相关论文
共 50 条
  • [21] Efficacy and Tolerability of Ziprasidone vs. Olanzapine in Naive First-Episode Schizophrenia: A 6-Week, Randomized, Open-Label, Flexible-Dose Study
    Li, Y. -M.
    Zhao, J. -P.
    Ou, J. -J.
    Wu, R. -R.
    PHARMACOPSYCHIATRY, 2012, 45 (05) : 177 - 181
  • [22] Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders:: Results from a large, prospective, open-label study
    Dittmann, Ralf W.
    Meyer, Eberhard
    Freisleder, Franz Joseph
    Remschmidt, Helmut
    Mehler-Wex, Claudia
    Junghanss, Jenny
    Hagenah, Ulrich
    Schulte-Markwort, Michael
    Poustka, Fritz
    Schmidt, Martin H.
    Schulz, Eberhard
    Maestele, Anneliese
    Wehmeier, Peter M.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2008, 18 (01) : 54 - 69
  • [23] Feuerstein Instrumental Enrichment Program for People With Schizophrenia After the First Episode of Psychosis: Protocol for an Open-Label Intervention Study
    Fonseca, Ana Olivia
    Gomes, July Silveira
    Novaes, Rafael Angulo Condoretti Barros
    Dias, Cintia Lopes
    Rodrigues, Maria Eva de Miranda Alves
    Gadelha, Ary
    Noto, Cristiano
    JMIR RESEARCH PROTOCOLS, 2024, 13
  • [24] Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study
    Potenza, MN
    Holmes, JP
    Kanes, SJ
    McDougle, CJ
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (01) : 37 - 44
  • [25] Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: An open-label, prospective trial
    Lindenmayer, JP
    Volavka, J
    Lieberman, J
    Sheitman, B
    Citrome, L
    Chakos, M
    Czobor, P
    Parker, B
    Iskander, A
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (04) : 448 - 453
  • [26] AN OPEN-LABEL STUDY OF FAMOTIDINE AS A TREATMENT FOR SCHIZOPHRENIA
    WHITEFORD, HA
    STEDMAN, TJ
    MCGRATH, JJ
    WELHAM, J
    POND, S
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 1995, 20 (03): : 239 - 240
  • [27] One-year open-label study of the cognitive efficacy of blonanserin in antipsychotic-naive first-episode schizophrenia
    Miyamoto, S.
    Tenjin, T.
    Miyake, N.
    Ojima, K.
    Ninomiya, Y.
    Kitajima, R.
    Ogino, S.
    Kaneda, Y.
    Sumiyoshi, T.
    Yamaguchi, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 57 - 58
  • [28] Open-label study of olanzapine in children with pervasive developmental disorder
    Kemner, C
    Willemsen-Swinkels, SHN
    de Jonge, M
    Tuynman-Qua, H
    van Engeland, H
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (05) : 455 - 460
  • [29] Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
    Faries, Douglas E.
    Ascher-Svanum, Haya
    Nyhuis, Allen W.
    Kinon, Bruce J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1399 - 1405
  • [30] Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: An open-label study
    Mozes, T
    Greenberg, Y
    Spivak, B
    Tyano, S
    Weizman, A
    Mester, R
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (03) : 311 - 317
12345